Abstracts | 93 perception bias was associated with trait anxiety [beta=0. 49, t=4.3, p<0.001, R-square=0.23, F(1,58) We tested the applicability of a previously-developed paliperidone palmitate 3-month (PP3M) population pharmacokinetic (pop-PK) model to PK data from Chinese and Japanese patients from a global PP3M phase-3 study (NCT01515423). A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the relationship between time course of paliperidone plasma concentrations following PP3M administration and relapse rates, as well as relevant risk factors. Methods: PK data from 1369 patients were used for external validation of a pop-PK model 1 previously developed on data from phase-1 and phase-3 studies 2,3
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Objectives:
We tested the applicability of a previously-developed paliperidone palmitate 3-month (PP3M) population pharmacokinetic (pop-PK) model to PK data from Chinese and Japanese patients from a global PP3M phase-3 study (NCT01515423). A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the relationship between time course of paliperidone plasma concentrations following PP3M administration and relapse rates, as well as relevant risk factors. Methods: PK data from 1369 patients were used for external validation of a pop-PK model 1 previously developed on data from phase-1 and phase-3 studies 2, 3 . Relevant covariate effects were body mass index (BMI) on volume of distribution; creatinine clearance on renal clearance; injection site, sex, injection volume on absorption parameters. The PK/PD analysis dataset included 1002 patients who were randomized to receive PP1M or PP3M in the double-blind phase.
Results:
The pop-PK model was successfully validated on the new PK data. No model refinement was needed to describe Chinese and Japanese PK data. PK/PD modeling showed that higher paliperidone exposure was associated with reduced relapse risk, with no major differences in relapse rates between PP1M and PP3M arms. Independently from paliperidone exposure, higher relapse hazard was identified for patients on concomitant benzodiazepine medication (+193% hazard; 95% confidence interval: 85-363%), and patients at Japanese centers (+129% hazard; 95% confidence interval: 36-283%).
Conclusions:
The previously-developed pop-PK model and covariates adequately captured the PK of PP3M from the current study. Race did not influence PP3M pharmacokinetics after the impact of BMI was incorporated in the model. PK/PD modeling of relapse rates evidenced an exposure-response relationship, i.e. reduced risk of relapse for higher paliperidone concentrations. Concomitant benzodiazepine use (possibly to treat residual/emergent symptoms) may be interpreted as an indicator of higher patient severity, and hence higher risk of relapse. In model-based simulations, the PP1M and PP3M arms appeared to display similar relapse rates over time. , randomized, multicenter non-inferiority study examined symptomatic remission and functional recovery in acutely-ill Asian patients with schizophrenia receiving paliperidone palmitate 3-month (PP3M) or 1-month (PP1M) long-acting injectable. Methods: Symptomatic remission (≤3 symptom score on P1, P2, P3, N1, N4, N6, G5, and G9 items of positive and negative symptom score for the last 6 months of 48-week DB treatment, on the basis of Andreason's criteria) and functional recovery (personal and social performance score>70 for the last 6 months of DB treatment) were evaluated in Asian patients with schizophrenia from this global study (NCT01515423 
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Abstract
Personality is an important factor in the pathogenesis of schizophrenia because it affects patients' symptoms, cognition and social functioning. Several studies have reported specific personality traits in patients with schizophrenia compared with healthy subjects. However, the results were inconsistent among studies, as the sample size in each study was not sufficient. The NEO Five-Factor Inventory (NEO-FFI) measures five personality traits: Neuroticism (N), Extraversion (E), Openness (O), Agreeableness (A) and Conscientiousness (C). Here, we performed a meta-analysis of these personality traits assessed by the NEO-FFI in 427 patients with schizophrenia and 455 healthy subjects from the published literature and investigated possible associations between schizophrenia and these traits. There was no publication bias for any traits (P>0.10). Because we found evidence of significant heterogeneity in all traits among the studies (P<0.10), we applied a random-effect model to perform the meta-analysis. Patients with schizophrenia showed a higher score for N and lower scores for E, O, A and C compared with healthy subjects (P<0.05). The effect sizes of these personality traits ranged from moderate to large. These differences were not affected by possible confounding factors, such as age and gender (P>0.05). These findings suggest that patients with schizophrenia have a unique personality profile compared with healthy subjects.
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